Comparison of topical nepafenac 0.1% with intravitreal dexamethasone implant for the treatment of Irvine-Gass syndrome
Author:
Corresponding Author:

Hande Guclu and Vuslat Pelitli Gurlu. Department of Ophthalmology, Faculty of Medicine, Trakya University, Edirne 22030, Turkey. hande83_toprakci@hotmail.com; vuslatgurlu@hotmail.com

  • Article
  • | |
  • Metrics
  • |
  • Reference [65]
  • |
  • Related [20]
  • | | |
  • Comments
    Abstract:

    AIM: To compare safety and efficacy of intravitreal dexamethasone (IVD) implant with topical nepafenac (TN) 0.1% in previously untreated Irvine-Gass syndrome (IGS) in clinical practice. METHODS: This was a retrospective study of 62 eyes with IGS after phacoemulsification with posterior chamber intraocular lens (IOL) implantation. None of the patients used treatment before IVD or TN. Best-corrected visual acuity (BCVA) with Early Treatment Diabetic Retinopathy Study chart (ETDRS), slit-lamp, intraocular pressure (IOP) measurement, fundus examination, spectral-domain optical coherence tomography (OCT) and fundus florescein angiography were performed to all subjects at baseline, 1, 3 and 6mo. RESULTS: The mean BCVA of the IVD group was 49.3±6.8, and the mean BCVA of the TN group was 32.9±7.3 ETDRS letters in post-treatment month 6. The mean central macular thickness (CRT) of IVD group was 266.6±53.5 µm and the mean CRT of TN group was 364.9±56.3 µm in post-treatment month 6. Baseline BCVA has correlation with final BCVA in TN group however there was no correlation between baseline BCVA and final BCVA in IVD group. CONCLUSION: IVD is found to be better than TN in controlling pseudophakic macular edema and improving visual acuity. IVD group also has significantly lower CRT however IOP is not significantly different between two groups in post-treatment month 6.

    Reference
    1 Irvine SR. A newly defined vitreous syndrome following cataract surgery. Am J Ophthalmol 1953;36(5):599-619.
    2 Drolsum L, Haaskjold E. Causes of decreased visual acuity after cataract extraction. J Cataract Refract Surg 1995;21(1):59-63.
    3 Barone A, Russo V, Prascina F, Delle Noci N. Short-term safety and efficacy of intravitreal bevacizumab for pseudophakic cystoid macular edema. Retina 2009;29(1):33-37.
    4 Yonekawa Y, Kim IK. Pseudophakic cystoid macular edema. Curr Opin Ophthalmol 2012;23(1):26-32.
    5 Dutra Medeiros M, Navarro R, Garcia-Arumí J, Mateo C, Corcóstegui B. Dexamethasone intravitreal implant for treatment of patients with recalcitrant macular edema resulting from irvine-gass syndrome. Invest Ophthalmol Vis Sci 2013;54(5):3320.
    6 Benitah NR, Arroyo JG. Pseudophakic cystoid macular edema. Int Ophthalmol Clin 2010;50(1):139-153.
    7 Reis A, Birnbaum F, Hansen LL, Reinhard T. Successful treatment of cystoid macular edema with valdecoxib. J Cataract Refract Surg 2007;33(4):682-685.
    8 Flach AJ. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc 1998;96:557-634.
    9 Cohen SM, Davis A, Cukrowski C. Cystoid macular edema after pars plana vitrectomy for retained lens fragments. J Cataract Refract Surg 2006;32(9):1521-1526.
    10 Mayer WJ, Kurz S, Wolf A, Kook D, Kreutzer T, Kampik A, Priglinger S, Haritoglou C. Dexamethasone implant as an effective treatment option for macular edema due to Irvine-Gass syndrome. J Cataract Refract Surg 2015;41(9):1954-1961.
    11 Rossetti L, Chaudhuri J, Dickersin K. Medical prophylaxis and treatment of cystoid macular edema after cataract surgery. The results of a meta-analysis. Ophthalmology 1998;105(3):397-405.
    12 Cicik ME, Doğan C, Arslan OŞ. Effect of intracameral ophthalmic cefuroxime solution (Aprokam®) in the prophylaxis of cataract surgery in patients with keratoplasty. Balkan Med J 2018;35(2):181-185.
    13 Shelsta HN, Jampol LM. Pharmacologic therapy of pseudophakic cystoid macular edema: 2010 update. Retina 2011;31(1):4-12.
    14 Sivaprasad S, Bunce C, Wormald R. Non-steroidal anti-inflammatory agents for cystoid macular oedema following cataract surgery: a systematic review. Br J Ophthalmol 2005;89(11):1420-1422.
    15 Wu L, Arevalo JF, Hernandez-Bogantes E, Roca JA. Intravitreal infliximab for refractory pseudophakic cystoid macular edema: results of the Pan-American Collaborative Retina Study Group. Int Ophthalmol 2012;32(3):235-243.
    16 Bellocq D, Pierre-Kahn V, Matonti F, et al. Effectiveness and safety of dexamethasone implants for postsurgical macular oedema including Irvine-Gass syndrome: the EPISODIC-2 study. Br J Ophthalmol 2017;101(3):333-341.
    17 Garcia JM, Isaac DL, Ávila MP. Dexamethasone 0.7 mg implants in the management of pseudophakic cystoid macular edema. Arq Bras Oftalmol 2016;79(2):113-115.
    18 Bellocq D, Korobelnik JF, Burillon C, Voirin N, Dot C, Souied E, Conrath J, Milazzo S, Massin P, Baillif S, Kodjikian L. Effectiveness and safety of dexamethasone implants for post-surgical macular oedema including Irvine-Gass syndrome: the EPISODIC study. Br J Ophthalmol 2015;99(7):979-983.
    19 Arevalo JF, Maia M, Garcia-Amaris RA, Roca JA, Sanchez JG, Berrocal MH, Wu L, Pan-American Collaborative Retina Study Group. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results. Ophthalmology 2009;116(8):1481-1487,1487.e1.
    20 Singh RP, Lehmann R, Martel J, Jong K, Pollack A, Tsorbatzoglou A, Staurenghi G, Cervantes-Coste Cervantes G, Alpern L, Modi S, Svoboda L, Adewale A, Jaffe GJ. Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: results of 2 randomized phase 3 studies. Ophthalmology 2017;124(6):776-785.
    21 Ke TL, Graff G, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation 2000;24(4):371-384.
    22 Kapin MA, Yanni JM, Brady MT, McDonough TJ, Flanagan JG, Rawji MH, Dahlin DC, Sanders ME, Gamache DA. Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac. Inflammation 2003;27(5):281-291.
    23 Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation 2000;24(4):357-370.
    24 London NJ, Chiang A, Haller JA. The dexamethasone drug delivery system: indications and evidence. Adv Ther 2011;28(5):351-366.
    25 Mylonas G, Georgopoulos M, Malamos P, Georgalas I, Koutsandrea C, Brouzas D, Sacu S, Perisanidis C, Schmidt-Erfurth U, Macula Study Group Vienna. Comparison of dexamethasone intravitreal implant with conventional triamcinolone in patients with postoperative cystoid macular edema. Curr Eye Res 2017;42(4):648-652.
    26 Ayar O, Alpay A, Koban Y, Akdemir MO, Yazgan S, Canturk Ugurbas S, Ugurbas SH. The effect of dexamethasone intravitreal implant on retinal nerve fiber layer in patients diagnosed with branch retinal vein occlusion. Curr Eye Res 2017;42(9):1287-1292.
    27 Gass JD, Norton EW. Cystoid macular edema and papilledema following cataract extraction: a fluorescein fundoscopic and angiographic study. 1966. Retina 2003;23(6 Suppl):646-661.
    28 Yüksel B, Uzunel UD, Kerci SG, Sağban L, Küsbeci T, Örsel T. Comparison of subtenon triamcinolone acetonide injection with topical nepafenac for the treatment of pseudophakic cystoid macular edema. Ocul Immunol Inflamm 2017;25(4):513-519.
    29 Schmier JK, Halpern MT, Covert DW, Matthews GP. Evaluation of costs for cystoid macular edema among patients after cataract surgery. Retina 2007;27(5):621-628.
    30 Wittpenn JR, Silverstein S, Heier J, Kenyon KR, Hunkeler JD, Earl M, Acular LS for Cystoid Macular Edema (ACME) Study Group. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low-risk cataract surgery patients. Am J Ophthalmol 2008;146(4):554-560.
    31 Henderson BA, Kim JY, Ament CS, Ferrufino-Ponce ZK, Grabowska A, Cremers SL. Clinical pseudophakic cystoid macular edema. Risk factors for development and duration after treatment. J Cataract Refract Surg 2007;33(9):1550-1558.
    32 Bélair ML, Kim SJ, Thorne JE, Dunn JP, Kedhar SR, Brown DM, Jabs DA. Incidence of cystoid macular edema after cataract surgery in patients with and without uveitis using optical coherence tomography. Am J Ophthalmol 2009;148(1):128-135.e2.
    33 Pande MV, Spalton DJ, Kerr-Muir MG, Marshall J. Postoperative inflammatory response to phacoemulsification and extracapsular cataract surgery: aqueous flare and cells. J Cataract Refract Surg 1996;22(Suppl 1): 770-774.
    34 Diestelhorst M, Aspacher F, Konen W, Krieglstein GK. The effect of flurbiprofen 0.03% eye drops on the blood aqueous barrier in extracapsular cataract extraction with IOL implantation. Int Ophthalmol 1991;15(2):69-73.
    35 Kraff MC, Sanders DR, McGuigan L, Raanan MG. Inhibition of blood-aqueous humor barrier breakdown with diclofenac. A fluorophotometric study. Arch Ophthalmol 1990;108(3):380-383.
    36 Flach AJ. Cyclo-oxygenase inhibitors in ophthalmology. Surv Ophthalmol 1992;36(4):259-284.
    37 Flach AJ. Topical nonsteroidal antiinflammatory drugs in ophthalmology. Int Ophthalmol Clin 2002;42(1):1-11.
    38 Lane SS, Modi SS, Lehmann RP, Holland EJ. Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. J Cataract Refract Surg 2007;33(1):53-58.
    39 Seth A, Ghosh B, Raina UK, Gupta A, Arora S. Intravitreal diclofenac in the treatment of macular edema due to branch retinal vein occlusion. Ophthalmic Surg Lasers Imaging Retina 2016;47(2):149-155.
    40 Soheilian M, Karimi S, Ramezani A, Montahai T, Yaseri M, Soheilian R, Peyman GA. Intravitreal diclofenac versus intravitreal bevacizumab in naive diabetic macular edema: a randomized double-masked clinical trial. Int Ophthalmol 2015;35(3):421-428.
    41 Soheilian M, Eskandari A, Ramezani A, Rabbanikhah Z, Soheilian R. A pilot study of intravitreal diclofenac versus intravitreal triamcinolone for uveitic cystoid macular edema. Ocul Immunol Inflamm 2013;21(2): 124-129.
    42 Tsilimbaris MK, Tsika C, Kymionis GD. Intravitreal ketorolac for the treatment of chronic cystoid macular edema after cataract surgery. Ther Clin Risk Manag 2016;12:177-182.
    43 Warren KA, Bahrani H, Fox JE. NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. Retina 2010;30(2):260-266.
    44 Ghanbari H, Kianersi F, Sonbolestan SA, Abtahi MA, Akbari M, Abtahi ZA, Abtahi SH. Intravitreal Diclofenac plus Bevacizumab versus Bevacizumab alone in treatment-naive diabetic macular edema: a randomized double-blind clinical trial. Int Ophthalmol 2017;37(4):867-874.
    45 Spitzer MS, Ziemssen F, Yoeruek E, Petermeier K, Aisenbrey S, Szurman P. Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema. J Cataract Refract Surg 2008; 34(1):70-75.
    46 Mitropoulos PG, Chatziralli IP, Peponis VG, Drakos E, Parikakis EA. Intravitreal ranibizumab for the treatment of irvine-gass syndrome. Ocul Immunol Inflamm 2015;23(3):225-231.
    47 Demirel S, Batioğlu F, Özmert E. Intravitreal ranibizumab for the treatment of cystoid macular edema in irvine-gass syndrome. Journal of Ocular Pharmacology and Therapeutics 2012;28(6):636-639.
    48 Lin CJ, Tsai YY. Use of aflibercept for the management of refractory pseudophakic macular edema in irvine-gass syndrome and literature review. Retin Cases Brief Rep 2018;12(1):59-62.
    49 Conway MD, Canakis C, Livir-Rallatos C, Peyman GA. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J Cataract Refract Surg 2003;29(1):27-33.
    50 Konstantopoulos A, Williams CP, Luff AJ. Outcome of intravitreal triamcinolone acetonide in postoperative cystoid macular oedema. Eye (Lond) 2008;22(2):219-222.
    51 Chin HS, Park TS, Moon YS, Oh JH. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina 2005;25(5):556-560.
    52 Chang-Lin JE, Burke JA, Peng Q, Lin T, Orilla WC, Ghosn CR, Zhang KM, Kuppermann BD, Robinson MR, Whitcup SM, Welty DF. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci 2011;52(7):4605-4609.
    53 Jain S, Thompson JR, Foot B, Tatham A, Eke T. Severe intraocular pressure rise following intravitreal triamcinolone: a national survey to estimate incidence and describe case profiles. Eye (Lond) 2014;28(4): 399-401.
    54 Theodoropoulou S, Ellabban AA, Johnston RL, Cilliers H, Mohamed Q, Sallam AB. Short-term safety of dexamethasone implant for treatment of macular edema due to retinal vein occlusion, in eyes with glaucoma or treated ocular hypertension. Graefes Arch Clin Exp Ophthalmol 2017;255(4):725-732.
    55 Malclès A, Dot C, Voirin N, Vié AL, Agard É, Bellocq D, Denis P, Kodjikian L. Safety of intravitreal dexamethasone implant (ozurdex): the SAFODEX study. incidence and risk factors of ocular hypertension. Retina 2017;37(7):1352-1359.
    56 Giganti M, Beer PM, Lemanski N, Hartman C, Schartman J, Falk N. Adverse events after intravitreal infliximab (Remicade). Retina 2010;30(1):71-80.
    57 Furino C, Boscia F, Recchimurzo N, Sborgia C, Alessio G. Intravitreal dexamethasone implant for refractory macular edema secondary to vitrectomy for macular pucker. Retina 2014;34(8):1612-1616.
    58 Evliyaoğlu F, Akpolat Ç, Kurt MM, Çekiç O, Nuri Elçioğlu M. Retinal vascular caliber changes after topical nepafenac treatment for diabetic macular edema. Cur Eye Res 2018;43(3):357-361.
    59 Kurt MM, Çekiç O, Akpolat Ç, Aslankurt M, Elçioğlu M. Vessel diameter study: intravitreal vs posterior subtenon triamcinolone acetonide injection for diabetic macular edema. Eye 2017;31(8):1155-1162.
    60 Wickremasinghe SS, Rogers SL, Gillies MC, Zhu MD, Wong TY. Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema. Invest Ophthalmol Vis Sci 2008;49(11): 4707-4711.
    61 Kurt MM, Çekiç O, Akpolat Ç, Elçioglu M. Effects of intravitreal ranibizumab and bevacizumab on the retinal vessel size in diabetic macular edema. Retina 2018;38(6):1120-1126.
    62 Yanni SE, Clark ML, Yang R, Bingaman DP, Penn JS. The effects of nepafenac and amfenac on retinal angiogenesis. Brain Res Bull 2010; 81(2-3):310-319.
    63 Pollack A, Staurenghi G, Sager D, Mukesh B, Reiser H, Singh RP. Prospective randomised clinical trial to evaluate the safety and efficacy of nepafenac 0.1% treatment for the prevention of macular oedema associated with cataract surgery in patients with diabetic retinopathy. Br J Ophthalmol 2017;101(4):423-427.
    64 Sudhalkar A, Chhablani J, Vasavada A, Bhojwani D, Vasavada V, Vasavada S, Medscape. Intravitreal dexamethasone implant for recurrent cystoid macular edema due to Irvine-Gass syndrome: a prospective case series. Eye (Lond) 2016;30(12):1549-1557.
    65 Sze AM, Luk FO, Yip TP, Lee GK, Chan CK. Use of intravitreal dexamethasone implant in patients with cataract and macular edema undergoing phacoemulsification. Eur J Ophthalmol 2015;25(2):168-172.
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

Guclu H, Pelitli Gurlu V. ,/et al.Comparison of topical nepafenac 0.1% with intravitreal dexamethasone implant for the treatment of Irvine-Gass syndrome. Int J Ophthalmol 2019;12(2):258-267

Copy
Share
Article Metrics
  • Abstract:1834
  • PDF: 664
  • HTML: 344
  • Cited by: 0
Publication History
  • Received:January 29,2018
  • Revised:April 25,2018
  • Online: January 03,2019